Clinical Trial

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

Study acronym: ASPIRE-201
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with Nucleos(t)ide Analogue (NAs).
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-14
Trial Details
NCT Number NCT07370207
Lead Sponsor AusperBio Therapeutics Inc.
Conditions Hepatitis B, Chronic
Enrollment 84 participants
Start Date 2026-03-06
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-04